Effect of Transdermal Testosterone and Oral Progesterone on Drug-Induced QT Interval Lengthening in Older Men: A Randomized, Double-Blind, Placebo-Controlled Crossover-Design Study

Circulation. 2019 Sep 24;140(13):1127-1129. doi: 10.1161/CIRCULATIONAHA.119.041395. Epub 2019 Sep 23.

Authors

Elena Tomaselli Muensterman¹, Heather A Jaynes¹, Kevin M Sowinski^{1

2}, Brian R Overholser^{1

2}, Changyu Shen³, Richard J Kovacs⁴, James E Tisdale^{1

2}

Affiliations

¹ College of Pharmacy, Purdue University, Indianapolis, IN (E.T.M., H.A.J., K.M.S., B.R.O., J.E.T.).
² Division of Clinical Pharmacology (K.M.S., B.R.O., J.E.T.), School of Medicine, Indiana University, Indianapolis.
³ Smith Center for Outcomes Research in Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA (C.S.).
⁴ Krannert Institute of Cardiology (R.J.K.), School of Medicine, Indiana University, Indianapolis.

No abstract available

Keywords: abnormalities, drug-induced; electrocardiography; long QT syndrome; progesterone; testosterone.

Publication types

Letter
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Cutaneous
Administration, Oral
Aged
Aged, 80 and over
Cross-Over Studies
Double-Blind Method
Electrocardiography
Female
Humans
Male
Placebos
Progesterone / therapeutic use*
Systole / physiology*
Testosterone / therapeutic use*
Torsades de Pointes / epidemiology*

Substances

Placebos
Testosterone
Progesterone

Grants and funding